



FOR IMMEDIATE RELEASE

Media Contact: Lan Lai-Minh, 905-281-6454 or 647-409-6148

HEALTH CANADA APPROVES ADVATE® 3000 IU DOSAGE STRENGTH

*-- New 3000 IU reduces number of infusions and saves time
for Canadians with Hemophilia A --*

MISSISSAUGA, ON, November 6, 2009 – Health Canada has approved a new 3000 IU (5mL) dosage strength of ADVATE® [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (rAHF-PFM)], a factor VIII recombinant used to prevent and control bleeding episodes in people living with hemophilia A. Available for the first time in Canada, the increased concentration of ADVATE 3000 IU means patients who need higher doses can infuse the same amount of treatment more easily and in less time using fewer vials.

Expected to be available to patients in Canada early in 2010, the ADVATE 3000 IU vial is packaged with BAXJECT II, a device that helps patients prepare recombinant treatment in an easy, fast and safe way with its needleless design and built-in filters.

“When treatment is simpler and more efficient, it can help patients be more compliant with their therapy,” said Dorine Belliveau, Hemophilia Nurse Coordinator at the Moncton Hospital, New Brunswick. “The new ADVATE 3000 IU dosage strength combined with BAXJECT II can reduce treatment time by up to half, creating a much quicker and easier process.”

ADVATE is indicated in hemophilia A (classical hemophilia) for the prevention and control of bleeding episodes. Infused directly into the bloodstream, it works by temporarily raising the level of factor VIII in the blood, thus allowing the body’s blood clotting process to function properly. ADVATE is the only full-length recombinant factor VIII therapy processed without blood or blood additives, including human albumin or other plasma protein additives.

“The new ADVATE 3000 IU offers patients with hemophilia A more choices to meet their individual treatment needs. Those who need higher dosages now have more flexibility and convenience. Infusing fewer vials means more rapid and more convenient treatment. This makes it easier for patients to manage hemophilia in their everyday lives and to adhere to their treatment regimens,” said Dr. Jerome Teitel, Director, Toronto & Central Ontario Hemophilia Program, St. Michael’s Hospital.

With the approval of the 3000IU (5mL) dosage strength, ADVATE is the only factor VIII therapy to offer people with hemophilia A in Canada the broadest selection of dosage strengths: 250 IU, 500 IU, 1000 IU, 1500 IU, 2000 IU and 3000 IU.

About ADVATE

ADVATE was developed in response to the needs of the hemophilia community, who called for the removal of human and animal blood-derived additives from recombinant factor VIII therapies. Since its introduction in 2003, more than six billion international units have been

distributed to date to treat people living with hemophilia A in 48 countries worldwide including Canada, the United States, 27 countries in the European Union, Argentina, Australia, Brazil, Chile, Colombia, Croatia, Hong Kong, Iceland, Japan, Malaysia, New Zealand, Norway, Puerto Rico, Singapore, South Korea, Suriname, Switzerland, Taiwan and Uruguay.

ADVATE should be administered cautiously in patients with previous hypersensitivity to constituents of Factor VIII preparations or known sensitivity to mouse or hamster proteins. The most common related adverse reactions observed during the ADVATE clinical studies include: headache, dizziness and pyrexia.

About Hemophilia A

People with hemophilia A do not produce adequate amounts of Factor VIII, which is necessary for blood to effectively clot. As a result, people with hemophilia A are prone to bleeding for a longer period of time than someone without the disease. If untreated, patients with severe hemophilia A can damage limbs or organs, and can even become life threatening. Hemophilia A affects 1 in 10,000 or about 3,000 Canadians.

Baxter Research and Development

Baxter focuses its scientific resources and leverages strategic collaborations to advance the treatment of hemophilia and blood clotting disorders. Building on its history of innovation, the company is developing therapies to provide less invasive dosing techniques, require less frequent infusions, and/or reduce the potential for inhibitor formation to improve the lives of people with bleeding disorders.

About Baxter

As a subsidiary of Baxter International Inc., Baxter Corporation (Canada) manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. More information: www.baxter.ca.